Skip to Main Content

Paper Details

Factors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer: ONCOSUR AVALOX Study.
Anticancer Res
2
2015
Bevacizumab, ER, HER2, HER2-negative Metastatic Breast Cancer, HRPBC, MBC, PATIENTS, Patients, TNBC, bevacizumab, breast cancer, hormone receptor, metastatic breast cancer, paclitaxel, patients, triple-negative breast cancer
Author NameAffiliation
Mar??a J Garc??aHospital General de Ciudad Real
Santiago González-MorenoHospital San Pedro de Alcantara
  • 1 - 2

Datasets

Release 1.2